Capillus® Laser Therapy Receives Medical Device License Approval In Canada
Becomes First Laser Therapy Cap Manufacturer to be Cleared by Health Canada
Miami, Florida (PRWEB) October 26, 2016
We look forward to providing health care providers and the patient community throughout Canada access to a safe and effective laser therapy treatment solution for hair loss, which has been inaccessible until now.
Capillus®, LLC, a medical device manufacturer focused on providing customers with the best products in treatment for hair loss, announced today that it has been issued a Class II Medical Device License by Health Canada for its laser hair therapy at-home laser caps. Capillus is the first low level laser therapy (LLLT) cap manufacturer to be cleared by Health Canada, the Canadian federal regulator responsible for licensing medical devices.
Capillus laser therapy caps use safe, low level lasers to energize hair follicles and spur new, natural hair growth. The lightweight Capillus laser caps, which are also cleared by the United States Food & Drug Administration, are discreet and allow patients to enjoy the proven benefits of laser hair restoration on their own schedule without having to visit a physician’s office. All are designed to be worn on the inside of an ordinary baseball cap or head covering, eliminating the “shame factor” typically associated with hair loss treatment. The routine is as simple as wearing the cap for 30 minutes, three times a week.
“The receipt of our Medical Device License from Health Canada, one of the leading and most advanced healthcare markets in the world, is another testament to the strong quality-support system we have in place to protect the best interest of our customer,” said Carlos Pina, chief executive officer, Capillus, LLC. “We look forward to providing health care providers and the patient community throughout Canada access to a safe and effective laser therapy treatment solution for hair loss, which has been inaccessible until now.”
The Class II Medical Device License demonstrates evidence of the device’s safety and effectiveness. It also legally permits the sale of Capillus’ complete line of laser hair therapy caps: Capillus272™ Pro, Capillus202™, and Capillus82™, which has been highly anticipated in the Canadian market for several months. Capillus will begin distribution in Canada immediately.
The announcement comes on the heels of Capillus’ ISO 13485:2003 certification last month, which was received through the Medical Device Single Audit Program (MDSAP) pilot and ensures Capillus meets current Good Manufacturing Practices set by the FDA. Capillus is the only company specializing in laser therapy for hair regrowth to receive the certification.
Capillus became the first low level laser therapy manufacturer to receive FDA clearance for male and female hair loss treatment in May 2016.
To learn more about laser hair restoration with Capillus, please visit https://www.capillus.com/ or call 888-272-9599.
ABOUT CAPILLUS, LLC
Capillus, LLC is a Miami-based medical device manufacturer & marketer of solutions for hair loss. Founded in 2012, the company is a resource for those battling hair loss. Capillus, LLC serves the physician and the consumer market with medical laser devices and cosmetic products. The company also connects patients to hair transplant surgeons & dermatologists for both surgical & non-invasive treatment options.
Capillus was founded in October 2012 and received its first FDA 510(k) clearance in January of 2015. Capillus has been manufacturing its medical laser devices since January 2015. The company moved to its present day 20,000 square foot location in the area of Doral to expand its manufacturing facilities in June of 2015 and has been experiencing steady growth with a total of 5 FDA 510(k) clearances for its four laser therapy models.
Building on its mission to provide customers with the best products in treatment of hair loss, all Capillus products cater to both women & men with thinning hair or at risk for thinning hair, a condition that affects up to 50% of adult women & 80% of adult men.